博碩士論文 106225017 詳細資訊




以作者查詢圖書館館藏 以作者查詢臺灣博碩士 以作者查詢全國書目 勘誤回報 、線上人數:4 、訪客IP:3.94.202.172
姓名 黃彥文(Yen-Wen Huang)  查詢紙本館藏   畢業系所 統計研究所
論文名稱 鑑別最佳添加藥物劑量的兩階段早期臨床試驗設計
相關論文
★ 藥物最低有效劑量之無母數鑑別★ 根據貝氏檢定建構的第一期臨床試驗設計
★ 第一期臨床試驗之貝氏調適設計★ 強餘震之即時貝氏預測
★ 臺灣地區地下水品質之統計研究★ 右設限存活資料之下每日可服劑量之研究
★ 集集餘震之統計研究★ 多群資料下最低有效劑量之聯合鑑別
★ 最大餘震規模之統計分析★ 最大餘震發生時間之統計分析
★ 地震預測之統計分析★ 加權Kaplan-Meier統計量之推廣
★ 鑑別藥物最低有效劑量之檢定★ 餘震序列RJ模型之貝氏分析
★ 藥物最低有效劑量之穩健鑑別★ 台灣強震之時間與規模預測模型
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   至系統瀏覽論文 ( 永不開放)
摘要(中) 摘要
本文設計早期臨床試驗以鑑別在混合藥中,除固定劑量的標準藥物外,添加藥物的最佳劑量。此一最佳添加藥物劑量,使得服用該混合藥物的毒性機率低於目標毒性機率,但是卻具有最大機率出現優於標準藥物的短期藥效。本文提出兩階段的早期臨床試驗設計,第一階段利用連續重評估法或嚴格控管過度劑量方法尋找最大耐受劑量,第二階段則在具有高原期劑量藥效的模型之下,比較混合藥物與標準藥物的藥效,以鑑別低於最大耐受劑量卻具有比標準藥物更高藥效的最低劑量。本文在不同的劑量毒性與劑量藥效情境下,比較本文所提設計與文獻中劑量漸增設計在鑑別最佳劑量的表現,以及試驗執行所需時間與人數的表現。根據研究顯示,本文所提設計選擇最佳添加藥物劑量的表現不劣於上述劑量漸增設計,但是本文所提設計於試驗執行所需時間與人數方面的表現,均優於該劑量漸增設計。

關鍵字: 高原期劑量藥效模型、早期臨床試驗、兩階段試驗設計、標準藥物、
混合藥物
摘要(英) Abstract
In this paper, we develop a two-stage design to identify the optimal dose of the additive component (OAD) in a combined drug, where the combined drug has toxicity probability less than the targeted toxicity probability (TTP) but most outperforms the standard drug in efficacy. In the first stage, different dose assignments for identifying the MTD are studied based on the CRM design working under the one-parameter logistic regression model for the dose-toxicity relationship. In the second stage, the group sequential design is used for dose escalation where the MTD is adjusted and the OAD is re-estimated under a plateaued dose-efficacy model. A simulation study is conducted to investigate the OAD estimation, over-toxic dose assignment and trial time of the proposed design and the competitive single-step designs. The proposed design does not suggest assign patients to receive the standard drug in the first stage. Moreover, the two-stage design is competitive to the single-stage designs in the OAD estimation, but the single-stage designs are time consuming and need more patients.
Key words : Plateau efficacy model, early clinical trial, two-stage design, standard drug,
combined drug.
關鍵字(中) ★ 高原期劑量藥效模型
★ 早期臨床試驗
★ 兩階段試驗設計
★ 標準藥物
★ 混合藥物
關鍵字(英) ★ Plateau efficacy model
★ early clinical trial
★ two-stage design
★ standard drug
★ combined drug
論文目次 目錄
摘要…………………………………………………………………….....................................I
Abstract………………………………………………………………......................................II
目錄………………………………………………………………...........................................III
第一章 研究目的與動機……………………………………………………………………...1
第二章 文獻回顧……………………………………………………………………...............5
2.1 第一期臨床試驗方法……………………………………………………..................5
2.2早期臨床試驗介紹……………………………………………………..….................9
第三章 研究方法…………………………………………………….....................................17
3.1第一期臨床試驗新添加藥物之對照組研究………………………………….…....17
3.2兩階段早期臨床試驗設計……………………………………………….................20
第四章 模擬研究…………………………………………………….....................................23
4.1模擬研究之設計…………………………………………………….........................23
4.2模擬研究結果 ……………………………………………………...........................23
第五章 結論與未來研究………………………………………………………….................28
參考文獻……………………………………………………………………………...............30
參考文獻 參考文獻
1. Babb J, Rogatko A and Zack S (1998). Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine, 17, 1103-1120.
2. Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, and Ratain MJ (2014). Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res, 20(16), 4210–4217
3. Guédé D, Reigner B, Vandenhende F, Derks M, Beyer U, Jordan P, Worth E, Diack C, Frey N and Peck R (2014). Bayesian adaptive designs in single ascending dose trials in healthy volunteers. British Journal of Clinical Pharmacology, 78(20), 393-400.
4. Bartroff J, Lai TL and Narasimhan B (2014). A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. Statistics in Medicine, 33, 2718-2735.
5. Riviere MK, Yuan Y, Jourdan JH, Dubois F and Zohar S (2016). Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research, 0(0), 1–16.
6. O’Quigley J, Pape M and Fisher L (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. Biometrics, 46(1), 33-48.
7. Thall PF and Cook JD (2004). Dose-Finding Based on Efficacy–Toxicity Trade-Offs. Biometrics, 60, 684–693.
8. Thall PF, Herrick RC, Nguyen HQ, Venier J and Norris JC(2014). Effective sample size for computing prior hyper-parameters in Bayesian phase I–II dose-finding. Clinical Trials, 11(6), 657–666.
指導教授 陳玉英(Yuh-Ing Chen) 審核日期 2019-7-25
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明